Puretech Health Financials
Puretech Health (PRTC) reported $4.7M in revenue for fiscal year 2025, down 3.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny revenue makes this look like an operating business, but the real mechanic is cash-funded balance-sheet consumption amid volatile non-cash earnings.
FY2024 produced net income of$27.8M alongside operating cash flow of-$134.4M , a mismatch that says reported profit did not reflect cash economics. FY2025 then swung to a-$110.1M loss while operating cash flow was still-$85.1M , reinforcing that earnings volatility is being driven mainly by non-cash accounting effects rather than by a business suddenly turning cash generative or cash destructive.
Despite the burn, near-term liquidity is not the immediate pressure point: FY2025 cash was
This is not a fixed-asset hungry model: FY2025 capex was just
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Puretech Health's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Puretech Health, and counted as zero in the overall score.
Puretech Health passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Puretech Health reported a net loss of $110.1M while operations used $85.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Puretech Health generated $4.7M in revenue in fiscal year 2025. This represents a decrease of 3.5% from the prior year.
Puretech Health reported -$110.1M in net income in fiscal year 2025. This represents a decrease of 496.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Puretech Health recorded an outflow of $85.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 36.6% from the prior year.
Puretech Health held $252.5M in cash against $11.1M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Puretech Health's ROE was -36.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 42.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Puretech Health spent $19.6M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 310.1% from the prior year.
Puretech Health invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 45.5% from the prior year.
Not reported for fiscal year 2025.
PRTC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M-3.5% | $4.8M+45.0% | $3.3M-78.7% | $15.6M-10.2% | $17.4M+47.8% | $11.8M+20.0% | $9.8M-52.7% | $20.7M |
| Interest Expense | $1.1M-17.8% | $1.3M-16.1% | $1.5M-22.1% | $2.0M-9.1% | $2.2M-7.3% | $2.4M-5.7% | $2.5M-90.4% | $25.9M |
| Income Tax | -$842K+79.0% | -$4.0M-113.1% | $30.5M+154.8% | -$55.7M-1583.5% | $3.8M-73.9% | $14.4M-87.2% | $112.4M+4961.2% | $2.2M |
| Net Income | -$110.1M-496.2% | $27.8M+141.7% | -$66.6M-79.8% | -$37.1M+40.9% | -$62.7M-1472.8% | $4.6M-98.8% | $366.1M+618.1% | -$70.7M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EPS (Diluted).
PRTC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $534.7M-11.3% | $602.6M-13.2% | $694.0M-1.2% | $702.6M-25.7% | $946.0M-4.4% | $990.0M+5.2% | $941.2M | N/A |
| Current Assets | $305.0M-21.0% | $386.3M+11.2% | $347.2M-10.1% | $386.2M-23.0% | $501.8M+21.1% | $414.3M+145.4% | $168.8M | N/A |
| Cash & Equivalents | $252.5M-10.0% | $280.6M+46.9% | $191.1M+27.5% | $149.9M-67.8% | $465.7M+15.3% | $403.9M+205.1% | $132.4M+13.1% | $117.1M |
| Accounts Receivable | $1.8M+15.5% | $1.5M-35.9% | $2.4M-80.0% | $11.9M+273.9% | $3.2M+24.1% | $2.6M+29.4% | $2.0M | N/A |
| Goodwill | $23.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $229.0M+17.6% | $194.7M-17.4% | $235.7M+52.0% | $155.1M-57.1% | $361.9M+7.6% | $336.5M+15.7% | $290.8M | N/A |
| Current Liabilities | $46.3M+11.9% | $41.4M-19.4% | $51.4M-47.0% | $96.9M-57.2% | $226.1M+25.0% | $180.9M+30.0% | $139.2M | N/A |
| Long-Term Debt | $11.1M-24.4% | $14.7M-19.6% | $18.3M-24.4% | $24.2M-16.8% | $29.0M-9.5% | $32.1M-8.1% | $34.9M | $0 |
| Total Equity | $305.7M-25.1% | $407.9M-11.0% | $458.2M-16.3% | $547.6M-6.3% | $584.1M-10.6% | $653.5M+0.5% | $650.4M+287.2% | $168.0M |
| Retained Earnings | -$77.2M-337.7% | $32.5M-61.2% | $83.8M-43.9% | $149.5M-25.2% | $199.9M-23.3% | $260.4M+2.4% | $254.4M | N/A |
Not reported in any period shown, so not listed: Inventory.
PRTC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$85.1M+36.6% | -$134.4M-26.9% | -$105.9M+40.8% | -$178.8M-13.0% | -$158.3M-20.1% | -$131.8M-34.3% | -$98.2M-34.8% | -$72.8M |
| Capital Expenditures | $6K-45.5% | $11K-84.3% | $70K-96.8% | $2.2M-60.9% | $5.6M+7.8% | $5.2M-57.4% | $12.1M+178.1% | $4.4M |
| Free Cash Flow | -$85.1M+36.6% | -$134.4M-26.8% | -$106.0M+41.4% | -$181.0M-10.5% | -$163.8M-19.6% | -$137.0M-24.2% | -$110.3M-42.9% | -$77.2M |
| Investing Cash Flow | $63.3M-73.7% | $240.9M+249.2% | $69.0M+164.3% | -$107.2M-154.3% | $197.4M-45.8% | $364.5M+472.5% | $63.7M+260.6% | -$39.6M |
| Financing Cash Flow | -$6.3M+62.7% | -$17.0M-121.7% | $78.1M+362.0% | -$29.8M-231.2% | $22.7M-41.5% | $38.9M-22.1% | $49.9M-68.2% | $156.9M |
| Share Buybacks | $19.6M+310.1% | $4.8M-75.6% | $19.6M-25.8% | $26.5M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
PRTC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Net Margin | -2362.8% | 575.4% | -2000.8% | -237.3% | -360.6% | 38.8% | 3732.7% | -340.6% |
| Return on Equity | -36.0%-42.8pp | 6.8%+21.3pp | -14.5%-7.8pp | -6.8%+4.0pp | -10.7%-11.4pp | 0.7%-55.6pp | 56.3%+98.4pp | -42.1% |
| Return on Assets | -20.6%-25.2pp | 4.6%+14.2pp | -9.6%-4.3pp | -5.3%+1.3pp | -6.6%-7.1pp | 0.5%-38.4pp | 38.9% | N/A |
| Current Ratio | 6.59-2.7x | 9.33+2.6x | 6.76+2.8x | 3.99+1.8x | 2.22-0.1x | 2.29+1.1x | 1.21 | N/A |
| Debt-to-Equity | 0.040.0x | 0.040.0x | 0.040.0x | 0.040.0x | 0.050.0x | 0.050.0x | 0.05+0.1x | 0.00 |
| FCF Margin | -1827.4% | -2783.3% | -3182.8% | -1158.7% | -942.3% | -1164.2% | -1124.6% | -371.9% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Where Puretech Health Ranks
Frequently Asked Questions
What is Puretech Health's annual revenue?
Puretech Health (PRTC) reported $4.7M in total revenue for fiscal year 2025. This represents a -3.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Puretech Health's revenue growing?
Puretech Health (PRTC) revenue declined by 3.5% year-over-year, from $4.8M to $4.7M in fiscal year 2025.
Is Puretech Health profitable?
No, Puretech Health (PRTC) reported a net income of -$110.1M in fiscal year 2025.
How much debt does Puretech Health have?
As of fiscal year 2025, Puretech Health (PRTC) had $252.5M in cash and equivalents against $11.1M in long-term debt.
What is Puretech Health's return on equity (ROE)?
Puretech Health (PRTC) has a return on equity of -36.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Puretech Health's free cash flow?
Puretech Health (PRTC) recorded an outflow of $85.1M in free cash flow during fiscal year 2025. This represents a 36.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Puretech Health's operating cash flow?
Puretech Health (PRTC) recorded an outflow of $85.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Puretech Health's total assets?
Puretech Health (PRTC) had $534.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Puretech Health's capital expenditures?
Puretech Health (PRTC) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Puretech Health's current ratio?
Puretech Health (PRTC) had a current ratio of 6.59 as of fiscal year 2025, which is generally considered healthy.
What is Puretech Health's debt-to-equity ratio?
Puretech Health (PRTC) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Puretech Health's return on assets (ROA)?
Puretech Health (PRTC) had a return on assets of -20.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Puretech Health's cash runway?
Based on fiscal year 2025 data, Puretech Health (PRTC) had $252.5M in cash against an annual operating cash burn of $85.1M. This gives an estimated cash runway of approximately 36 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Puretech Health's Piotroski F-Score?
Puretech Health (PRTC) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Puretech Health's earnings high quality?
Puretech Health (PRTC) reported a net loss of $110.1M while operations used $85.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Puretech Health?
Puretech Health (PRTC) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.